Population
Patients with coronary artery disease (stable coronary artery disease or acute coronary syndrome)
Design
Review
Key result
Dual antiplatelet therapy choice and duration require an individualized approach based on clinical presentation, ischemic versus hemorrhagic risk, and treatment plan in patients with coronary artery disease.
Authors
Loading...
Supports risk-stratified DAPT in CAD; leaves open updates from post-2017 trials.
This review summarizes the evidence and 2017 ESC guidelines for tailored dual antiplatelet therapy in patients with coronary artery disease.
Rakočević et al. (2018) conducted a review in Coronary artery disease. Dual antiplatelet therapy (DAPT) was evaluated. Dual antiplatelet therapy choice and duration require an individualized approach based on clinical presentation, ischemic versus hemorrhagic risk, and treatment plan in patients with coronary artery disease.